Zinc affects the proteolytic stability of Apolipoprotein E in an isoform-dependent way

Neurobiology of Disease

Volumn 81, Issue , 2015, Pages 38-48

  Xu, He ^a   Gupta, Veer B ^b   Martins, Ian J ^b   Martins, Ralph N ^b   Fowler, Christopher J ^a   Bush, Ashley I ^a   Finkelstein, David I ^a   Adlard, Paul A ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

Author keywords

Apolipoprotein E; Proteolytic stability; Zinc

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CHYMOTRYPSIN; COPPER; IRON; KALLIKREIN; THROMBIN; ZINC; APOLIPOPROTEIN E; CHELATING AGENT; EDETIC ACID; ENZYME INHIBITOR; ISOPROTEIN; SERINE PROTEINASE; TRACE ELEMENT;

ALZHEIMER DISEASE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; GENOTYPE; HUMAN; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; BLOOD; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PLASMA;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; CHELATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EDETIC ACID; ENZYME INHIBITORS; HUMANS; PLASMA; PROTEIN ISOFORMS; SERINE PROTEASES; THROMBIN; TRACE ELEMENTS; ZINC;

EID: 84950325643     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.06.016     Document Type: Article

References (65)

1. Barnham K.J., Bush A.I. Biological metals and metal-targeting compounds in major neurodegenerative diseases. Chem. Soc. Rev. 2014, 43(19):6727-6749.
2. Baum L., et al. Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability. Biometals 2010, 23(1):173-179.
3. Beffert U., Stolt P.C., Herz J. Functions of lipoprotein receptors in neurons. J. Lipid Res. 2004, 45(3):403-409.
4. Bush A.I., Tanzi R.E. The galvanization of beta-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(11):7317-7319.
5. Bush A.I. Drug development based on the metals hypothesis of Alzheimer's disease. J. Alzheimers Dis. 2008, 15(2):223-240.
6. Buyue Y., Whinna H.C., Sheehan J.P. The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis. Blood 2008, 112(8):3234-3241.
7. Castellano J.M., et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 2011, 3(89):89ra57.
8. Cerf M.E., Raidoo D.M. Immunolocalization of plasma kallikrein in human brain. Metab. Brain Dis. 2000, 15(4):315-323.
9. Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261(5123):921-923.
10. Corder E.H., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994, 7(2):180-184.
11. Cruchaga C., et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum. Mol. Genet. 2012, 21(20):4558-4571.
12. Crutcher K.A., Lilley H.N., Anthony S.R., Zhou W., Narayanaswami V. Full-length apolipoprotein E protects against the neurotoxicity of an apoE-related peptide. Brain Res. 2010, 1306:106-115.
13. Cuajungco M.P., et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J. Biol. Chem. 2000, 275(26):19439-19442.
14. Elliott D.A., et al. Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol. Aging 2011, 32(2):257-271.
15. Farrer L.A., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278(16):1349-1356.
16. Frieden C., Garai K. Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(23):8913-8918.
17. Fryer J.D., et al. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 2005, 280(27):25754-25759.
18. Gonzalez C., et al. Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur. J. Clin. Investig. 1999, 29(7):637-642.
19. Gozzo A.J., et al. Heparin modulation of human plasma kallikrein on different substrates and inhibitors. Biol. Chem. 2006, 387(8):1129-1138.
20. Gupta V.B., et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 2011, 76(12):1091-1098.
21. Hanson A.J., et al. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol. 2013, 70(8):972-980.
22. Harris F.M., et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(19):10966-10971.
23. Hauser P.S., Narayanaswami V., Ryan R.O. Apolipoprotein E: from lipid transport to neurobiology. Prog. Lipid Res. 2011, 50(1):62-74.
24. Hirsch-Reinshagen V., et al. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 2004, 279(39):41197-41207.
25. Huang Y., Mahley R.W. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol. Dis. 2014, 72(Pt A):3-12.
26. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 2006, 66(2 Suppl. 1):S79-S85.
27. Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol. Med. 2010, 16(6):287-294.
28. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148(6):1204-1222.
29. Huang X., et al. Alzheimer's disease, beta-amyloid protein and zinc. J. Nutr. 2000, 130(5S Suppl.):1488S-1492S.
30. Huang Y., et al. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(15):8838-8843.
31. Hudry E., et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci. Transl. Med. 2013, 5(212):212ra161.
32. Huntington J.A. Thrombin inhibition by the serpins. J. Thromb. Haemost. 2013, 11(Suppl. 1):254-264.
33. Hwang J.J., Park M.H., Choi S.Y., Koh J.Y. Activation of the Trk signaling pathway by extracellular zinc. Role of metalloproteinases. J. Biol. Chem. 2005, 280(12):11995-12001.
34. Jones P.B., et al. Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-beta in human Alzheimer brain. PLoS One 2011, 6(1):e14586.
35. Karlin S., Zhu Z.Y. Classification of mononuclear zinc metal sites in protein structures. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(26):14231-14236.
36. Lee J.Y., et al. Apolipoprotein E ablation decreases synaptic vesicular zinc in the brain. Biometals 2010, 23(6):1085-1095.
37. Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013, 9(2):106-118.
38. Liu Q., et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007, 56(1):66-78.
39. Liu J., Gao B.B., Feener E.P. Proteomic identification of novel plasma kallikrein substrates in the astrocyte secretome. Transl. Stroke Res. 2010, 1(4):276-286.
40. Liu M., Kuhel D.G., Shen L., Hui D.Y., Woods S.C. Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 303(9):R903-R908.
41. Mahley R.W., Huang Y. Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology. Acta Neurol. Scand. Suppl. 2006, 185:8-14.
42. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240(4852):622-630.
43. Martinez-Morillo E., et al. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathol. 2014, 127(5):633-643.
44. Marques M.A., Owens P.A., Crutcher K.A. Progress toward identification of protease activity involved in proteolysis of apolipoprotein e in human brain. J. Mol. Neurosci. 2004, 24(1):73-80.
45. Marques M.A., Tolar M., Harmony J.A., Crutcher K.A. A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. Neuroreport 1996, 7(15-17):2529-2532.
46. McCord M.C., Aizenman E. The role of intracellular zinc release in aging, oxidative stress, and Alzheimer's disease. Front. Aging Neurosci. 2014, 6:77.
47. Miyata M., Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 1996, 14(1):55-61.
48. Morrow J.A., et al. Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry 2000, 39(38):11657-11666.
49. Morrow J.A., et al. Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. J. Biol. Chem. 2002, 277(52):50380-50385.
50. Nuttall J.R., Oteiza P.I. Zinc and the aging brain. Genes Nutr. 2014, 9(1):379.
51. Rasmussen K.L., Tybjaerg-Hansen A., Nordestgaard B.G., Frikke-Schmidt R. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann. Neurol. 2015, 77(2):301-311.
52. Rensen P.C., et al. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J. Biol. Chem. 2000, 275(12):8564-8571.
53. Riddell D.R., et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 2008, 28(45):11445-11453.
54. Tamboli I.Y., Heo D., Rebeck G.W. Extracellular proteolysis of apolipoprotein E (apoE) by secreted serine neuronal protease. PLoS One 2014, 9(3):e93120.
55. Tanzi R.E., Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001, 32(2):181-184.
56. Tolar M., Marques M.A., Harmony J.A., Crutcher K.A. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J. Neurosci. 1997, 17(15):5678-5686.
57. Tolar M., et al. Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. J. Neurosci. 1999, 19(16):7100-7110.
58. Ulrich J.D., et al. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol. Neurodegener. 2013, 8:13.
59. Wahrle S.E., et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 2004, 279(39):40987-40993.
60. Wahrle S.E., et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 2008, 118(2):671-682.
61. Wang C., et al. Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer's disease. PLoS One 2014, 9(2):e89041.
62. Wirnt R. Chymotrypsin. Methods Enzym. Anal. 1974, 1009-1012.
63. Xu H., Finkelstein D.I., Adlard P.A. Interactions of metals and Apolipoprotein E in Alzheimer's disease. Front. Aging Neurosci. 2014, 6:121.
64. Xiong Y., et al. Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation. Neurobiol. Aging 2013, 34(3):745-756.
65. Zhou W., Scott S.A., Shelton S.B., Crutcher K.A. Cathepsin D-mediated proteolysis of apolipoprotein E: possible role in Alzheimer's disease. Neuroscience 2006, 143(3):689-701.